Biotech Industry · global
Basecamp raises $140 million to advance AI-designed in vivo cell therapies
From designing DNA to modifying cells in the human body, Basecamp is trying to narrow the gap between the two. The new funding will support model training and therapy development, but the evidence remains preclinical, with no timeline yet for human trials.
Modifying cells directly inside patients is a threshold that cell therapy hopes to cross: if achieved, it could reduce the complex procedures involved in processing cells outside the body. Basecamp Research is committing resources to this goal, announcing on September 23 that it had completed a $140 million Series C funding round to advance AI-designed biological sequences toward therapeutic development.
The round was led by S32, with participants including NVIDIA and Menlo Ventures’ Anthology Fund. Reuters reported that the company’s valuation reached $800 million; its previous round was a $60 million Series B led by Singular in October 2024. The new funding will be used to train the next generation of EDEN biological foundation models and advance a product pipeline beginning with in vivo cell therapies.
The core of the technology connects sequence design with genomic integration. According to the company, EDEN can design long, complex DNA sequences that can then be paired with large serine recombinases to integrate the sequences into specific locations in the genome. The development goal is to reprogram cells inside patients, with potential future applications in cancer and autoimmune diseases; these remain intended applications of the platform, rather than demonstrated therapeutic effects.
The data behind the models come from Basecamp’s proprietary Trillion Gene Atlas. The company says this genomic database was built through collaborations spanning more than 30 countries, allowing the models to learn sequence patterns across different organisms. However, broad data coverage does not directly translate into reliability for medical use; the key remains whether model-generated sequences can function consistently and safely in target cells.
Existing experiments offer preliminary indications. Citing a preprint, Genetic Engineering & Biotechnology News reported that approximately half of the tested EDEN-generated large serine recombinases were active in human cells, and that the research also demonstrated the insertion of chimeric antigen receptor (CAR) sequences into primary human T cells. This supports the biological functionality of the designed products, but cell experiments cannot establish a therapy’s delivery efficiency, sustained activity or safety once administered to humans, and the preprint results still require further scrutiny.
The next test will therefore be to combine functional molecular tools into therapeutic products that can be evaluated, including confirming whether sequences integrate at the intended locations and assessing the long-term behavior of modified cells. Reuters noted that although Basecamp announced preclinical progress, it did not provide a timeline for starting human trials. This funding round adds development resources, but experimental and clinical validation are still needed to demonstrate that patients can benefit.